Krystal Biotech Financial Statements
NASDAQ: KRYSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Krystal Biotech revenue and earnings
In fiscal 2025, Krystal Biotech generated $389.1 million in revenue, up 33.9% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $204.8 million (+129.7% year over year), for a net margin of 52.6% versus a median of 26.1% in the prior 5 years. Operating margin was 41.5%.
Diluted earnings per share came in at $6.84, up from $3.00.
Summary generated from market data by MetaCap's automated system. Methodology
Krystal Biotech income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20212022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 389.13M | 290.51M | 50.70M | 0 | 0 | — | — | — | — | — |
| Revenue growth (YoY) | +33.94% | +473.02% | — | — | — | — | — | — | — | — |
| Operating Expenses | 227.84M | 224.77M | 160.32M | 145.20M | 68.28M | 33.00M | 22.08M | 11.92M | 4.77M | 1.14M |
| Research & Development | 58.05M | 53.58M | 46.43M | 42.46M | 27.88M | 17.94M | 15.62M | 7.76M | 3.21M | 741.00K |
| Selling, General & Admin | 146.74M | 113.63M | 98.29M | 77.73M | — | — | — | — | — | — |
| Operating Income | 161.29M | 65.75M | -109.62M | -145.20M | -68.28M | -33.00M | -22.08M | -11.92M | -4.77M | -1.14M |
| Interest Expense | — | — | 0 | 0 | 1.49M | 0 | — | — | — | — |
| Other Income (Expense) | — | — | — | — | — | — | — | — | -3.15M | -7.00K |
| Pretax Income | 189.47M | 95.36M | 12.90M | -139.97M | -69.57M | — | — | — | — | — |
| Income Tax | -15.36M | 6.20M | 1.97M | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Net Income | 204.83M | 89.16M | 10.93M | -139.97M | -69.57M | -32.17M | -19.09M | -10.89M | -7.92M | -1.15M |
| Net Income growth (YoY) | +129.74% | +715.58% | — | — | — | — | — | — | — | — |
| EPS (Basic) | 7.08 | 3.12 | 0.40 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -1.31 |
| EPS (Diluted) | 6.84 | 3.00 | 0.39 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -1.31 |
| Shares Outstanding (Basic) | 28.94M | 28.59M | 27.15M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 877.49K |
| Shares Outstanding (Diluted) | 29.95M | 29.74M | 27.75M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 877.49K |
| EBITDA | 167.02M | 71.72M | -104.61M | -141.14M | -65.51M | -31.15M | -20.99M | -11.78M | -4.75M | -1.14M |
| Operating Margin | 41.45% | 22.63% | -216.21% | — | — | — | — | — | — | — |
| Net Margin | 52.64% | 30.69% | 21.56% | — | — | — | — | — | — | — |
This table shows 10 annual periods of Krystal Biotech's income statement, from FY 2025 back to FY 2016, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow KRYS's reporting calendar. What is a income statement?